Literature DB >> 23601421

The role of ghrelin in anorexia-cachexia syndromes.

Bobby Guillory1, Andres Splenser, Jose Garcia.   

Abstract

Anorexia, sarcopenia, and cachexia are common complications of many chronic conditions including cancer, rheumatoid arthritis, HIV infection, aging, and chronic lung, heart, or kidney disease. Currently, there is no effective treatment for muscle atrophy or wasting conditions although they typically take a significant toll on the quality of life of patients and are associated with poor prognosis and decreased survival. Ghrelin affects multiple key pathways in the regulation of body weight, body composition, and appetite in the setting of cachexia that may lead to an increase in appetite and growth hormone secretion and a reduction in energy expenditure and inflammation. The net effect is increased lean body mass and fat mass preservation. In this chapter, we review the mechanisms of action of ghrelin and present the available data in animal models and human trials using ghrelin or ghrelin mimetics in different settings of cachexia.
Copyright © 2013 Published by Elsevier Inc. Published by Elsevier Science & Technology.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23601421     DOI: 10.1016/B978-0-12-410473-0.00003-9

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  12 in total

Review 1.  Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.

Authors:  Yu Bai; Yunxia Hu; Yanhua Zhao; Xizhong Yu; Junwei Xu; Zhiyun Hua; Zhiqiang Zhao
Journal:  Support Care Cancer       Date:  2017-01-10       Impact factor: 3.603

Review 2.  Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment.

Authors:  Sumbul Ali; Ji-an Chen; Jose M Garcia
Journal:  Curr Opin Support Palliat Care       Date:  2013-12       Impact factor: 2.302

3.  Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile.

Authors:  Claudio Pietra; Yasuhiro Takeda; Naoko Tazawa-Ogata; Masashi Minami; Xia Yuanfeng; Elizabeth Manning Duus; Robert Northrup
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-09-30       Impact factor: 12.910

4.  Acylated and unacylated ghrelin inhibit atrophy in myotubes co-cultured with colon carcinoma cells.

Authors:  Xianliang Zeng; Sizeng Chen; Yang Yang; Zhao Ke
Journal:  Oncotarget       Date:  2017-08-24

5.  Oral Treatment with the Ghrelin Receptor Agonist HM01 Attenuates Cachexia in Mice Bearing Colon-26 (C26) Tumors.

Authors:  Fabienne O Villars; Claudio Pietra; Claudio Giuliano; Thomas A Lutz; Thomas Riediger
Journal:  Int J Mol Sci       Date:  2017-05-05       Impact factor: 5.923

6.  ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.

Authors:  D Currow; J S Temel; A Abernethy; J Milanowski; J Friend; K C Fearon
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

7.  Levels of the Novel Endogenous Antagonist of Ghrelin Receptor, Liver-Enriched Antimicrobial Peptide-2, in Patients with Rheumatoid Arthritis.

Authors:  Vera Francisco; Sulay Tovar; Javier Conde; Jesús Pino; Antonio Mera; Francisca Lago; Miguel Angel González-Gay; Carlos Dieguez; Oreste Gualillo
Journal:  Nutrients       Date:  2020-04-06       Impact factor: 5.717

Review 8.  Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.

Authors:  David C Currow; Matthew Maddocks; David Cella; Maurizio Muscaritoli
Journal:  Int J Mol Sci       Date:  2018-11-05       Impact factor: 5.923

Review 9.  Neuroactive peptides as putative mediators of antiepileptic ketogenic diets.

Authors:  Carmela Giordano; Maddalena Marchiò; Elena Timofeeva; Giuseppe Biagini
Journal:  Front Neurol       Date:  2014-04-29       Impact factor: 4.003

10.  Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.

Authors:  Shailesh M Advani; Pragati G Advani; Helena M VonVille; Syed H Jafri
Journal:  BMC Cancer       Date:  2018-11-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.